Hypolipidemic activity of Anethum graveolens in rats

Phytotherapy Research

Volumn 22, Issue 3, 2008, Pages 372-375

  Hajhashemi, Valiollah ^a   Abbasi, Naser ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anethum graveolens; Essential oil; Hypolipidemic activity

Indexed keywords

ALPHA PHELLANDRENE; ANTILIPEMIC AGENT; CARVONE; CHOLESTEROL; CLOFIBRATE; ESSENTIAL OIL; ETHER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIMONENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PINENE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DILL; DISTILLATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HEART PROTECTION; HYPERLIPIDEMIA; HYPOLIPIDEMIC ACTIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; RAT; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ANETHUM GRAVEOLENS; ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OILS, VOLATILE; PHYTOTHERAPY; PLANT COMPONENTS, AERIAL; PLANT EXTRACTS; RATS; RATS, WISTAR; TRIGLYCERIDES;

ANETHUM GRAVEOLENS; ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 40849131007     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2329     Document Type: Article

References (32)

1. Adams RP. 1995. Identification of Essential Oil Components by Gas Chromatography/Mass Spectroscopy. Allured Publishing Company: Carol Stream.
2. Alberts AW, Chen J, Kuron G et al. 1980. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutarylcoenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957-3961.
3. Allain CC, Poon LS, Chan GS, Richmond W, Fu PC. 1974. Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475.
4. Amin GR. 1991. Popular Medicinal Plants of Iran. Vol. 1. Ministry of Health Publications: Tehran, 101.
5. Anderson JW, Johnstone BM, Cook-Newell ME. 1995. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333: 279-282.
6. Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. 2003. Therapeutic applications of fenugreek. Altern Med Rev 8: 20-27.
7. Bhandari U, Sharma JN, Zafar R. 1998. The protective action of ethanolic ginger (Zingiber officinal) extract in cholesterol fed rabbits. J Ethnopharmacol 61: 167-171.
8. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. 1983. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80: 4124-4128.
9. British Pharmacopoeia. 1993. Vol. 2, HMSO: London, A137-A138.
10. Bucolo G, David H. 1973. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476-482.
11. Choi JS, Yokozawa T, Oura H. 1991. Antihyperlipidemic effect of flavonoids from Prunus davidiana. J Nat Prod 54: 218-224.
12. Ebn-e Sina A. 1988. Ghanoon dar Teb. Vol. 2. Soroosh Press: Tehran.
13. El-Hazmi MA, Warsy AS. 2001. Evaluation of serum cholesterol and triglyceride levels in 1-6-year-old Saudi children. J Trop Pediatr 47: 181-185.
14. Evans WC, Trease GE. 1996. Trease and Evans' Pharmacognosy, 14th edn. WB Saunders Company: London, 264-265.
15. Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F. 1988. Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287-294.
16. Friedwald WT, Levy IR, Friedrickson SD. 1972. Estimation of concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
17. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. 1973. Hyperlipidaemia in coronary heart disease 11. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorders, combined hyperlipidaemia. J Clin Invest 52: 1544-1568.
18. Hardman JG, Limbird LE. 2001. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill: New York.
19. Harrison D, Kathy KG, Hornig B, Drexler H. 2003. Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A-11A.
20. Jackson R, Beagle R. 1995. Evidence-based management of dyslipidaemia. Lancet 346: 1440-1442.
21. Keys A. 1975. Coronary heart disease, the global picture. Atherosclerosis 22: 149-192.
22. Leung AY, Foster S. 1996. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. John Wiley and Sons: New York, 210-212.
23. Lipid Research Clinics Program. 1984a. The lipid research clinics coronary primary prevention trial results. i. Reduction in incidence of coronary heart disease. JAMA 251: 251-364.
24. Lipid Research Clinics Program. 1984b. The lipid research clinics coronary primary prevention trial results. ii. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374.
25. Mclafferty FW, Stauffer DB. 1991. The Important Peak Index of the Registry of Mass Spectral Data. John Wiley and Sons: New York.
26. Orekhov AN, Grunwald J. 1997. Effects of garlic on atherosclerosis. Nutrition 13: 656-663.
27. Rang HP, Dale MM, Ritter JM. 1995. Pharmacology, 3rd edn. Churchill Livingstone: Edinburgh, 323-330.
28. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz IDJR. 1992. Measurement of low density lipoprotein cholesterol (LDL-C) in serum. Clin Chem 38: 150-160.
29. Sandra P, Bicchi C. 1987. Capillary Gas Chromatography in Essential Oil Analysis. Huethig Publications: Heidelberg, 259-274.
30. Thompson Coon JS, Ernest E. 2003. Herbs for serum cholesterol reduction: a systematic view. J Fam Pract 52: 468-478.
31. Yazdanparast R, Alavi M. 2001. Antihyperlipidemic and antihypercholesterolemic effects of Anethum graveolens leaves after removal of furocoumarins. Cytobios 105: 189-191.
32. Zargari A. 1991. Medicinal Plants. Vol. 2. Tehran University Publications: Tehran, 528-531.